New hope for kidney patients with Hard-to-Match immune systems
NCT ID NCT05145296
First seen Jan 10, 2026 · Last updated Jun 12, 2026 · Updated 31 times
Summary
This study tested two drugs, daratumumab and belatacept, in 5 highly sensitized dialysis patients waiting for a kidney transplant. The goal was to safely reduce the antibodies that make it very hard to find a compatible donor kidney. The trial was stopped early, but it aimed to help these patients get a transplant and keep the new kidney longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SENSITISATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chu Grenoble
La Tronche, 38700, France
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.